Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade...

Area of Science:

• Urology
• Oncology
• Clinical Trials

Background:

• Low-grade non-muscle-invasive urothelial cancer frequently recurs post-transurethral resection of bladder tumor (TURBT).
• Effective adjuvant intravesical therapies are crucial for reducing recurrence and improving outcomes.

Purpose of the Study:

• To evaluate the efficacy of immediate post-TURBT intravesical gemcitabine instillation in preventing recurrence of suspected low-grade non-muscle-invasive urothelial cancer compared to saline.
• To assess the impact on tumor progression and patient survival.

Main Methods:

• A randomized, double-blind clinical trial involving 406 patients across 23 US centers.
• Patients received either intravesical gemcitabine or saline immediately after TURBT.
• Follow-up included cystoscopy and cytology for up to 4 years to monitor recurrence, progression, and survival.

Main Results:

• Gemcitabine significantly reduced the 4-year recurrence risk by 34% compared to saline (35% vs. 47%; HR, 0.66; P<.001).
• In patients with confirmed low-grade disease, gemcitabine reduced recurrence by 37% (34% vs. 54%; HR, 0.53; P=.001).
• No significant differences were observed in progression to muscle invasion or overall mortality; adverse events were low-grade.

Conclusions:

• Immediate intravesical gemcitabine instillation following TURBT is effective in significantly reducing the recurrence of low-grade non-muscle-invasive urothelial cancer.
• This single-instillation therapy represents a valuable option for managing bladder cancer recurrence.
• Further research is warranted to compare gemcitabine with other intravesical agents.